- Home
- INSE vs URGN Comparison
INSE vs URGN Comparison
Compare INSE & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSE
- URGN
- Stock Information
- Founded
- INSE 2002
- URGN 2004
- Country
- INSE United States
- URGN United States
- Employees
- INSE N/A
- URGN N/A
- Industry
- INSE Computer Software: Prepackaged Software
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- INSE Technology
- URGN Health Care
- Exchange
- INSE Nasdaq
- URGN Nasdaq
- Market Cap
- INSE 222.8M
- URGN 181.2M
- IPO Year
- INSE N/A
- URGN 2017
- Fundamental
- Price
- INSE $8.82
- URGN $12.99
- Analyst Decision
- INSE Buy
- URGN Strong Buy
- Analyst Count
- INSE 5
- URGN 8
- Target Price
- INSE $12.20
- URGN $23.00
- AVG Volume (30 Days)
- INSE 175.6K
- URGN 5.5M
- Earning Date
- INSE 08-07-2025
- URGN 08-12-2025
- Dividend Yield
- INSE N/A
- URGN N/A
- EPS Growth
- INSE 3507.71
- URGN N/A
- EPS
- INSE 2.43
- URGN N/A
- Revenue
- INSE $295,200,000.00
- URGN $91,871,000.00
- Revenue This Year
- INSE $3.05
- URGN $36.65
- Revenue Next Year
- INSE $1.22
- URGN $88.35
- P/E Ratio
- INSE $3.46
- URGN N/A
- Revenue Growth
- INSE N/A
- URGN 8.98
- 52 Week Low
- INSE $6.51
- URGN $3.42
- 52 Week High
- INSE $11.61
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- INSE 69.68
- URGN 60.49
- Support Level
- INSE $7.30
- URGN $12.87
- Resistance Level
- INSE $8.58
- URGN $13.93
- Average True Range (ATR)
- INSE 0.34
- URGN 1.58
- MACD
- INSE 0.12
- URGN 0.05
- Stochastic Oscillator
- INSE 100.00
- URGN 69.51
About INSE Inspired Entertainment Inc.
Inspired Entertainment Inc is a gaming technology company based in the United States. Its core business involves the development of Virtual Sports and Server-Based Gaming systems with associated terminals and digital content to regulate betting, gaming, and lottery operators around the world. It operates through four segments, namely Gaming, Virtual Sports, Interactive, and Leisure. The company generates maximum revenue from the Gaming segment. Its Gaming segment supplies gaming terminals as well as gaming software and games for the terminals provided to betting offices, casinos, gaming halls, and high street adult gaming centers. Geographically, it derives a majority of revenue from the UK.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.